Fennec Pharmaceuticals Inc (FENC)vsVertex Pharmaceuticals Inc (VRTX)
FENC
Fennec Pharmaceuticals Inc
$8.70
-5.02%
HEALTHCARE · Cap: $302.21M
VRTX
Vertex Pharmaceuticals Inc
$446.83
-0.03%
HEALTHCARE · Cap: $107.89B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 23857% more annual revenue ($12.22B vs $51.00M). VRTX leads profitability with a 35.5% profit margin vs -16.4%. FENC appears more attractively valued with a PEG of 1.47. VRTX earns a higher WallStSmart Score of 68/100 (B-).
FENC
Hold37
out of 100
Grade: F
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for FENC.
Margin of Safety
+53.1%
Fair Value
$952.53
Current Price
$446.83
$505.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 72.6% year-over-year
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -22.2% — below average capital efficiency
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : FENC
The strongest argument for FENC centers on Revenue Growth. Revenue growth of 72.6% demonstrates continued momentum. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : FENC
The primary concerns for FENC are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
FENC profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.
FENC carries more volatility with a beta of 1.08 — expect wider price swings.
FENC is growing revenue faster at 72.6% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (68/100 vs 37/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Fennec Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops candidate products for use in the treatment of cancer in the United States. The company is headquartered in Research Triangle Park, North Carolina.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?